EverSource Wealth Advisors LLC Buys 305 Shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ)

EverSource Wealth Advisors LLC grew its stake in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ) by 96.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The firm owned 620 shares of the specialty pharmaceutical company’s stock after acquiring an additional 305 shares during the quarter. EverSource Wealth Advisors LLC’s holdings in Jazz Pharmaceuticals were worth $76,000 as of its most recent SEC filing.

Other institutional investors have also recently modified their holdings of the company. IFP Advisors Inc bought a new stake in shares of Jazz Pharmaceuticals during the 4th quarter valued at $25,000. Jones Financial Companies Lllp raised its holdings in shares of Jazz Pharmaceuticals by 75.1% during the 4th quarter. Jones Financial Companies Lllp now owns 303 shares of the specialty pharmaceutical company’s stock worth $37,000 after buying an additional 130 shares in the last quarter. UMB Bank n.a. raised its holdings in shares of Jazz Pharmaceuticals by 70.9% during the 4th quarter. UMB Bank n.a. now owns 311 shares of the specialty pharmaceutical company’s stock worth $38,000 after buying an additional 129 shares in the last quarter. Lindbrook Capital LLC raised its holdings in shares of Jazz Pharmaceuticals by 82.6% during the 4th quarter. Lindbrook Capital LLC now owns 389 shares of the specialty pharmaceutical company’s stock worth $48,000 after buying an additional 176 shares in the last quarter. Finally, Itau Unibanco Holding S.A. raised its holdings in shares of Jazz Pharmaceuticals by 63.2% during the 3rd quarter. Itau Unibanco Holding S.A. now owns 444 shares of the specialty pharmaceutical company’s stock worth $49,000 after buying an additional 172 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Jazz Pharmaceuticals Stock Down 0.5 %

Shares of NASDAQ:JAZZ opened at $139.51 on Wednesday. The business’s 50 day simple moving average is $130.22 and its two-hundred day simple moving average is $121.18. The firm has a market cap of $8.47 billion, a P/E ratio of 19.65, a PEG ratio of 1.04 and a beta of 0.44. The company has a debt-to-equity ratio of 1.46, a quick ratio of 3.74 and a current ratio of 4.26. Jazz Pharmaceuticals plc has a 52-week low of $99.06 and a 52-week high of $148.06.

Analyst Upgrades and Downgrades

JAZZ has been the subject of a number of research analyst reports. Truist Financial boosted their price target on Jazz Pharmaceuticals from $220.00 to $230.00 and gave the stock a “buy” rating in a report on Thursday, March 6th. HC Wainwright boosted their price target on Jazz Pharmaceuticals from $200.00 to $217.00 and gave the stock a “buy” rating in a report on Monday, March 10th. JPMorgan Chase & Co. boosted their price target on Jazz Pharmaceuticals from $200.00 to $209.00 and gave the stock an “overweight” rating in a report on Wednesday, February 26th. Cantor Fitzgerald cut Jazz Pharmaceuticals from an “overweight” rating to a “neutral” rating and upped their target price for the stock from $140.00 to $150.00 in a report on Wednesday, February 26th. Finally, Piper Sandler reaffirmed an “overweight” rating and issued a $176.00 target price (up previously from $163.00) on shares of Jazz Pharmaceuticals in a report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Buy” and an average price target of $187.71.

Insiders Place Their Bets

In related news, EVP Neena M. Patil sold 3,800 shares of the stock in a transaction that occurred on Thursday, February 27th. The stock was sold at an average price of $144.87, for a total transaction of $550,506.00. Following the completion of the sale, the executive vice president now directly owns 33,318 shares of the company’s stock, valued at approximately $4,826,778.66. This trade represents a 10.24 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, CEO Bruce C. Cozadd sold 1,500 shares of the stock in a transaction that occurred on Thursday, January 2nd. The shares were sold at an average price of $123.43, for a total value of $185,145.00. Following the sale, the chief executive officer now directly owns 425,525 shares of the company’s stock, valued at $52,522,550.75. The trade was a 0.35 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 28,736 shares of company stock worth $4,022,825. Corporate insiders own 4.20% of the company’s stock.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.